HH,
Happy to accept your sentiment. Please explain how we find the money to last another year for an approval and then, what, wait 6 months after that to start generating revenue? And how do we surmount corruption from BP and political headwinds near term. I am a large shareholder. I am very angry about the executive compensation approval before ANY FDA approval. What responsibility will our management have if they fail? The answer - NONE. They will simply sell their millions of shares beforehand and say “oh well, we tried.”
We the shareholders were just given I giant F you by NP. We are the ones taking serious risk at his point and he is doing nothing to assuage our concerns. On the contrary, he is giving us hopes, promises and half truths (HIV RTF is just the latest example with the receptor count rejection).
I have not sold shares....yet. But every investor ought to flood CytoDyn with emails demanding clear answers and setting EXACTING expectations for CytoDyn from this point on. Ask Nadar directly if he plans to sell his shares BEFORE we have an approval. I guarantee he will not promise that. We have EVERY RIGHT to be angry and frustrated at this point in our investment. The goal post continually move, communications literally SUCK, and these guys are paying themselves for producing NOTHING..
At the end of the day I have tremendous belief in the drug. But this point I have almost none in our management. I don’t want to hear about a SINGLE other basket trial or application of Leronlimab from this point on until we get a drug approval for either COVID or HIV.
I pray the executives at CytoDyn take a cursory look at these boards. They should be rightfully alarmed at the change in sentiment of shareholders, even though now they get paid regardless of performance.
NOT HAPPY AT ALL!
News 
Market Data 
Discover 
